• ENGLISH
  • FRANCAIS
  • Services
    • Services Overview
    • Clinical Trial Operations
      • Protocol Development and Study Design
      • Feasibility and Study Start Up
      • Patient Recruitment
      • Project Management
      • Clinical Operations
      • Centralized Monitoring
      • Decentralized Clinical Trials (DCT)
      • Centralized eTMF
      • Medical Services
    • Regulatory and Drug Development Consulting
      • Clinical Strategy
      • Nonclinical
      • Chemistry, Manufacturing, and Controls (CMC)
      • Regulatory Affairs
      • GxP Strategy Consulting
      • Publishing and Submissions
      • Medical Writing
    • Government and Public Health Services
    • Biometrics
      • Biostatistics and Statistical Programming
      • Data Management
    • Clinical Pharmacology Modeling Simulation
      • Clinical Pharmacology Integrated Drug Development
      • Model Informed Dose & Drug Development (MIDD)
      • Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
      • DMPK and Translational Discovery and Development
  • Therapeutic Expertise
    • Therapeutic Expertise Overview
    • By Subject
      • Oncology and Hematology
      • Rare Diseases and Orphan Drugs
      • Infectious Disease and Vaccine
      • Cell and Gene Therapy
      • Central Nervous System
      • Autoimmune and Inflammation
      • Allergy and Asthma
    • By Phase
  • Company
    • About Us
    • History
    • News
    • Events
    • Leadership
    • Mission, Vision, Values
  • Resources
    • Resource Library
    • Blogs
    • Case Studies
    • Podcasts
    • Webinars
    • White Papers
  • Careers
    • Careers Overview
    • Job Listings
    • CRA Academy and Fellows Program
  • Contact Us
    • Contact Us
    • Request for Proposal
  • ENGLISH
  • FRANCAIS
  • Services
    • Services Overview
    • Clinical Trial Operations
      • Protocol Development and Study Design
      • Feasibility and Study Start Up
      • Patient Recruitment
      • Project Management
      • Clinical Operations
      • Centralized Monitoring
      • Decentralized Clinical Trials (DCT)
      • Centralized eTMF
      • Medical Services
    • Regulatory and Drug Development Consulting
      • Clinical Strategy
      • Nonclinical
      • Chemistry, Manufacturing, and Controls (CMC)
      • Regulatory Affairs
      • GxP Strategy Consulting
      • Publishing and Submissions
      • Medical Writing
    • Government and Public Health Services
    • Biometrics
      • Biostatistics and Statistical Programming
      • Data Management
    • Clinical Pharmacology Modeling Simulation
      • Clinical Pharmacology Integrated Drug Development
      • Model Informed Dose & Drug Development (MIDD)
      • Pharmacometrics (PMx), Pharmacokinetics, Pharmacodynamics (PK/PD)
      • DMPK and Translational Discovery and Development
  • Therapeutic Expertise
    • Therapeutic Expertise Overview
    • By Subject
      • Oncology and Hematology
      • Rare Diseases and Orphan Drugs
      • Infectious Disease and Vaccine
      • Cell and Gene Therapy
      • Central Nervous System
      • Autoimmune and Inflammation
      • Allergy and Asthma
    • By Phase
  • Company
    • About Us
    • History
    • News
    • Events
    • Leadership
    • Mission, Vision, Values
  • Resources
    • Resource Library
    • Blogs
    • Case Studies
    • Podcasts
    • Webinars
    • White Papers
  • Careers
    • Careers Overview
    • Job Listings
    • CRA Academy and Fellows Program
  • Contact Us
    • Contact Us
    • Request for Proposal
  1. Home
  2. Services
  3. Clinical Pharmacology Modeling Simulation
  4. DMPK and Translational Discovery and Development
  5. Nonclinical PK, TK, and PD Analyses
    • Drug-Drug Interaction (DDI) Strategy
    • Nonclinical PK, TK, and PD Analyses
    • Nonclinical Strategy, Study Design, and Analysis

Nonclinical PK, TK, and PD Analyses

  • DMPK and Translational Discovery and Development
  • Drug-Drug Interaction (DDI) Strategy
  • Nonclinical PK, TK, and PD Analyses
  • Nonclinical Strategy, Study Design, and Analysis

Characterizing a therapeutic’s pharmacokinetics (PK) and pharmacodynamics (PD) begins during nonclinical development and continues throughout clinical development. The methods used to perform clinical PK analyses (for example, noncompartmental analysis) are identical to those used for nonclinical PK analyses, and by extension, toxicokinetic (TK) analyses. The only difference is that nonclinical PK involves doses in the anticipated clinically therapeutic range whereas TK involves higher doses as part of toxicology or safety pharmacology studies.

These analyses generate PK parameters that are useful measures of systemic exposure. The exposures may be correlated with therapeutic or toxic responses and can even be linked with biomarkers that represent PD effects (which, in the case of safety and toxicity are often referred to as toxicodynamic [TD] effects). Determining exposure-response (E-R) and PK/PD relationships are important for early evaluation of the therapeutic index of a new molecular entity (NME) and are important for translation of nonclinical results to predict likely outcomes in humans for first-in-human (FIH) dose selection.

Our experts at Allucent can support the entire range of toxicity studies that are required from early development through clinical development and registration. We provide nonclinical PK, TK, and PD analyses across all types of therapeutics (small to large molecules) and every route of administration. We have experience designing, analyzing, and interpreting PK, TK, and PD data from complex nonclinical study designs, such as immunogenicity and biodistribution data for safety and efficacy evaluation. Whether you need PK, TK, or PD analyses, interpretation of results, translational modeling and simulation of E-R and PK/PD relationships, advice on next steps, or any other nonclinical consulting services, our team will work with you to determine the most appropriate and cost-effective options for your program.

Nonclinical PK, TK, and PD Services

  • Noncompartmental analyses (NCA) of PK, TK, and PD data
  • SEND (CDISC compliant) data programming
  • Nonclinical PK/PD and E-R modeling
  • Translational modeling and simulation
    • Allometric scaling / population PK (popPK)
    • Physiologically-based PK modeling (PBPK)

Contact Us

Let us partner with your team on bringing new therapies to light. Get in touch to get started.

CONTACT US

  • Services
    • Clinical Trial Operations
    • Regulatory and Drug Development Consulting
    • Government and Public Health Services
    • Biometrics
    • Clinical Pharmacology Modeling Simulation
  • Therapeutic Expertise
    • Oncology and Hematology
    • Rare Diseases and Orphan Drugs
    • Infectious Disease and Vaccine
    • Cell and Gene Therapy
    • Central Nervous System
    • Autoimmune and Inflammation
    • Allergy and Asthma
  • Company
    • About Us
    • News
    • Events
  • Privacy Policy
  • English
  • Francais

© 2023 Allucent. All rights

North American Headquarters
2000 Centregreen Way
Suite 300
Cary, North Carolina 27513
+1 919-361-2286

United Kingdom Headquarters
1st Floor, One Station Square,
Bracknell, Berkshire
RG12 1QB United Kingdom
T: +44 (0) 1344 891121
F: +44 (0) 1344 890335

European Headquarters
Stationsplein Noord-Oost 438
1117 CL Schiphol
The Netherlands
+31 20-4350-580